Company: OCEA
Filing Date: 2025-04-08
Form Type: 10-K
Source: 0001641172-25-003155
Chunk: 2628

Company: Ocean Biomedical, Inc.
Filing Date: 2025-04-08
Form: 10-K
Item: Item 1
Chunk 2628
---
 management’s attention from our core business;

    ●
    substantial
    damages for infringement, which we may have to pay if a court decides that the product candidate or technology at issue infringes
    on or violates the third-party’s rights, and, if the court finds that the infringement was willful, we could be ordered to
    pay treble damages and the patent owner’s attorneys’ fees;

101

    ●
    a
    court prohibiting us from developing, manufacturing, marketing or selling our product candidates, or from using our proprietary technologies,
    unless the third-party licenses its product rights to us, which it is not required to do;

    ●
    if
    a license is available from a third-party, we may have to pay substantial royalties, upfront fees and other amounts, and/or grant
    cross-licenses to intellectual property rights for our products and any license that is available may be nonexclusive, which could
    result in our competitors gaining access to the same intellectual property; and

    ●
    redesigning
    our product candidates or processes so they do not infringe, which may not be possible or may require substantial monetary expenditures
    and time.

Some
of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially
greater resources. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material
adverse effect on our ability to raise the funds necessary to continue our operations or could otherwise have a material adverse effect
on our business, results of operations, financial condition and prospects. Furthermore, because of the substantial amount of discovery
required in connection with intellectual property litigation or administrative proceedings, there is a risk that some of our confidential
information could be compromised by disclosure.

We
may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time-consuming
and unsuccessful.

Competitors
may infringe our patents or the patents of our current or future licensors. To counter infringement or unauthorized use, we may be required
to file infringement claims, which can be expensive and time-consuming. In addition, in an infringement proceeding, a court may decide
that one or more of our patents is not valid or is unenforceable, or may refuse to stop the other party from using the technology at
issue on the grounds that our patents do not cover the technology in question or for other reasons. An adverse result in any litigation
or